The effect of recombinant human erythropoietin on the treatment of anemia of prematurity

Abstract

Objective: to assess the efficacy of erythropoietin in the prevention and treatment of anemia of prematurity, correlating the use of this drug with weight gain, length, and head circumference and comparing two administration schemes of he same weekly dose: daily use and twice a week.Methods: the study comprised 42 premature newborns with gestational age up to 33 weeks, birthweight up to 1550 g, and postnatal age between 10 and 35 days. The newborns were randomized into three groups: patients in group 1 received seven daily doses of 100 U/kg erythropoietin per week; patients in group 2 received two 350 U/kg erythropoietin doses per week; and patients in group 3 did not receive the drug. Hematologic measurements, blood transfusion requirements, and growth rates were followed during therapy.Results: cases and controls did not differ with respect to weight, length, head circumference, and total time of hospital stay. At the end of the study, no significant difference was observed in the platelet count measurement means, white blood cell count, and ferritin levels in the three groups. However, the final hematocrit and hemoglobin values of patients who did not receive erythropoietin were significantly lower than those of patients who received the drug. The absolute reticulocyte count mean was significantly higher in patients who received erythropoietin after two weeks of treatment when compared with those patients who did not receive the drug. Patients in group 1 e 2 received fewer excessive transfusions (2 or more) than patients in group 3. The administration of 700 U/kg/week erythropoietin significantly reduced the number of excessive blood transfusions. There is no significant difference in blood transfusion volume between patients who received erythropoietin on a daily basis and those who received the drug twice weekly.Conclusions: the use of erythropoietin did not influence weight gain and growth. The administration of 700 U/kg/week erythropoietin in premature infants with gestational age up to 33 weeks and birthweight up to 1550 g stimulates erythropoiesis and significantly reduces excessive blood transfusion requirements. Erythropoietin showed to be a safe and well tolerated medication, with no short-term side effects in the study population.J Pediatr (Rio J) 2001; 77 (2): 75-83: erythropoietin, anemia of prematurity, transfusion, premature. ResumoObjetivos: a proposta do presente estudo foi avaliar a eficácia da eritropoetina na prevenção e tratamento da anemia da prematuridade, correlacionar o uso desta medicação com o ganho de peso, comprimento e perímetro cefálico dos pacientes. Foi realizada também uma comparação entre o uso de eritropoetina diariamente e o uso duas vezes por semana, na mesma dose semanal.Métodos: ensaio clínico que avaliou 42 recém-nascidos prematuros, com até 33 semanas de idade gestacional, peso de nascimento até 1550g e idade pós-natal entre 10 e 35 dias de vida. Os recém-nascidos foram randomizados em três grupos. Os pacientes do grupo 1 receberam 7 doses diárias, de 100U/kg c...

A Comparison of Once- and Thrice-Weekly Erythropoietin Dosing for the Treatment of Anaemia of Prematurity

“…2 However, significant variations were noted in the EPO dosing regimen and the duration of treatment in these studies. 3,4 EPO at a dose of 250 IU/kg thrice-weekly for 6 weeks is a commonly practised regimen based on previous larger trials and is the current treatment protocol for infants with AOP in our neonatal intensive care unit (NICU).…”

Peran Eritropoetin pada Anemia Prematuritas

“…16 Pemberian eritropoetin 700 U/kg/minggu pada bayi prematur dengan umur kehamilan kurang dari 33 minggu dan berat badan lahir kurang dari 1550 gram terjadi stimulasi eritropoesis dan secara bermakna terjadi pengurangan pemberian transfusi darah. 15,17,18 Pemberian eritropoetin pada bayi prematur dengan berat badan di bawah atau sama dengan 1250 gram menunjukkan kadar feritin lebih rendah dibandingkan dengan yang tidak mendapat eritropoetin. 18 Sedangkan pemberian eritropoetin pada bayi berat badan lahir amat sangat rendah tidak ada perbedaan volume tranfusi darah dibandingkan dengan yang tidak mendapat eritropoetin.…”

Η Δράση Των Αντιοξειδωτικών Μορίων U – 74389 G Και Της Ερυθροποιητίνης, Σε Πειραματικό Πρότυπο Ισχαιμίας / Επαναιμάτωσης Θήλεων Γεννητικών Οργάνων Αρουραίου

“…Οι Rocha VL. et al μέτρησαν 67 τελικές τιμές hb νεογνών με αναιμία προωρότητας που δεν έλαβαν ΕΡΟ σημαντικά λιγότερη από αυτήν νεογνών που έλαβαν είτε 7 ημερήσιες δόσεις 100 U/kg ΕΡΟ, ή 2 δόσεις 350 U/kg ΕΡΟ εβδομαδιαίως. Δεν υπήρξε σημαντική διαφορά μεταξύ των 2 τελευταίων ομάδων ασθενών.…”

“…λήψη σιδήρου. Οι Rocha VL et al μέτρησαν 91 τελικές τιμές hct πρόωρων βρεφών < 33 weeks και βάρους γέννησης < 1550 g που έλαβαν 700 U/kg/εβδομαδιαίως ΕΡΟ, διεγείροντας την ερυθροποίηση, σημαντικώς περισσότερο απ' ότι οι μάρτυρες. Οι Lin CL et al μέτρησαν 92 σημαντικώς αυξημένο Hct μετά i.v.…”